孟鲁司特钠治疗小儿哮喘的有效性及安全性

Efficacy and safety of Montelukast Sodium in the treatment of asthma in children

目的研究孟鲁司特钠治疗小儿哮喘的有效性及安全性。方法选取我院2016年8月~2017年12月收治的100例哮喘患儿作为研究对象,按照随机数字表法分为观察组(50例)与对照组(50例)。观察组采用孟鲁司特钠治疗,对照组采用常规治疗,比较两组的总有效率、不良反应总发生率、咳嗽消失时间、哮喘消失时间、肺部哮鸣音消失时间、第1秒用力呼气容量(FEV1)、第1秒钟用力呼吸容积/用力肺活量(FEV1/FVC)指标。结果观察组的总有效率高于对照组,差异有统计学意义(P<0.05);观察组的不良反应总发生率显著低于对照组,差异有统计学意义(P<0.05)。观察组的咳嗽消失时间(4.21±1.02)d、哮喘消失时间(5.65±1.02)d、肺部哮鸣音消失时间(6.22±1.03)d,均短于对照组,差异均有统计学意义(P<0.05)。观察组FEV1、FEV1/FVC均优于对照组,差异有统计学意义(P<0.05)。结论孟鲁司特钠治疗小儿哮喘的有效性显著,具有一定的安全性,能显著改善患儿各项临床症状,值得推广应用。

Objective To study the efficacy and safety of Montelukast Sodium in the treatment of asthma in children.Methods 100 children with asthma treated in our hospital from August 2016 to December 2017 were selected as the research subjects. According to the random digital table method, the patients were divided into the observation group（50 cases） and the control group（50 cases）. The observation group was treated with Montelukast Sodium, and the control group was treated with routine treatment. The total effective rate, the total incidence of adverse reaction, the time of disappearance of cough, the time of disappearance of asthma, the time of disappearance of lung wheezing sound, FEV1 and FEV1/FVC index were compared in the two groups of asthmatic children. Results The total effective rate of children in the observation group was higher than that of the control group, the difference was statistically significant（P〈0.05）, and the incidence of adverse reaction in the observation group was significantly lower than that in the control group（P〈0.05）. The disappearance time of cough in the observation group（4.21±1.02） d, the time of asthma disappearance（5.65±1.02） d and the disappearing time of lung wheezing sound（6.22±1.03） d, were shorter than those in the control group, the differences were statistically significant（P〈0.05）. The 1 second forced expiratory volume（FEV1） and first second forced breathing volume/forced vital capacity（FEV1/FVC） in the observation group were better than those in the control group, and the differences were statistically significant（P〈0.05）. Conclusion Montelukast Sodium is very effective in the treatment of childhood asthma. It is safe and can significantly improve the clinical symptoms of children. It is worth pupulation and application.